Strategies to enhance CAR-T persistence

Abstract Chimeric antigen receptor T (CAR-T) cell therapy has significantly improved the life expectancy for patients with refractory or relapse B cell lymphoma. As for B cell acute lymphoblastic leukemia (B-ALL), although the primary response rate is promising, the high incidence of early relapse h...

Full description

Bibliographic Details
Main Authors: Yue Liu, Lingna An, Ruihao Huang, Jingkang Xiong, Haoyu Yang, Xiaoqi Wang, Xi Zhang
Format: Article
Language:English
Published: BMC 2022-11-01
Series:Biomarker Research
Subjects:
Online Access:https://doi.org/10.1186/s40364-022-00434-9

Similar Items